{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:55:47Z","timestamp":1761929747494,"version":"3.40.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,12,31]],"date-time":"2014-12-31T00:00:00Z","timestamp":1419984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s13318-014-0249-y","type":"journal-article","created":{"date-parts":[[2014,12,30]],"date-time":"2014-12-30T07:22:26Z","timestamp":1419924146000},"page":"231-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats"],"prefix":"10.1007","volume":"41","author":[{"given":"Jin-Seok","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Hyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,31]]},"reference":[{"key":"249_CR1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2174\/1389200033489389","volume":"4","author":"LZ Benet","year":"2003","unstructured":"Benet LZ, Cummins CL, Wu CY (2003) Transporter\u2013enzyme interactions: implications for predicting drug\u2013drug interactions from in vitro data. Curr Drug Metab 4:393\u2013398","journal-title":"Curr Drug Metab"},{"key":"249_CR2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00005344-198601000-00006","volume":"8","author":"JL Blackshear","year":"1986","unstructured":"Blackshear JL, Orlandi C, Williams GH, Hollenberg NK (1986) The renal response to diltiazem and nifedipine: comparison with nitroprusside. J Cardiovasc Pharmacol 8:37\u201343","journal-title":"J Cardiovasc Pharmacol"},{"key":"249_CR3","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/00498250010021684","volume":"30","author":"JJ Bogaards","year":"2000","unstructured":"Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131\u20131152","journal-title":"Xenobiotica"},{"key":"249_CR4","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/S0149-2918(00)80078-8","volume":"23","author":"J Chilcott","year":"2001","unstructured":"Chilcott J, Tappenden P, Jones ML, Wight JP (2001) A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 23:1792\u20131823","journal-title":"Clin Ther"},{"key":"249_CR5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/BF03191168","volume":"34","author":"DH Choi","year":"2009","unstructured":"Choi DH, Li C, Choi JS (2009) Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats. Eur J Drug Metab Pharmacokinet 34:163\u2013168","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"249_CR6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/bdd.1905","volume":"35","author":"JS Choi","year":"2014","unstructured":"Choi JS, Choi JS, Choi DH (2014) Effects of licocharcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A. Biopharm Drug Dispos 35:382\u2013390","journal-title":"Biopharm Drug Dispos"},{"key":"249_CR7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1073\/pnas.86.2.695","volume":"86","author":"C Cordon-Cardo","year":"1989","unstructured":"Cordon-Cardo C, O\u2019Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at bloodbrain barrier sites. Proc Natl Acad Sci 86:695\u2013698","journal-title":"Proc Natl Acad Sci"},{"key":"249_CR8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/abio.1997.2145","volume":"248","author":"CL Crespi","year":"1997","unstructured":"Crespi CL, Miller VP, Penman BW (1997) Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248:188\u2013190","journal-title":"Anal Biochem"},{"key":"249_CR9","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1124\/jpet.300.3.1036","volume":"300","author":"CL Cummins","year":"2002","unstructured":"Cummins CL, Jacobsen W, Benet LZ (2002) Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 300:1036\u20131045","journal-title":"J Pharmacol Exp Ther"},{"key":"249_CR10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2165\/00003088-200241040-00001","volume":"41","author":"MM Doherty","year":"2002","unstructured":"Doherty MM, Charman WN (2002) The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 41:235\u2013253","journal-title":"Clin Pharmacokinet"},{"key":"249_CR11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.biopha.2009.04.031","volume":"63","author":"M Dorababu","year":"2009","unstructured":"Dorababu M, Nishimura A, Prabha T, Naruhashi K, Sugioka N, Takada K, Shibata N (2009) Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine. Biomed Pharmacother 63:697\u2013702","journal-title":"Biomed Pharmacother"},{"key":"249_CR12","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","volume":"38","author":"GK Dresser","year":"2000","unstructured":"Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic\u2013pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38:41\u201357","journal-title":"Clin Pharmacokinet"},{"key":"249_CR13","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1016\/0006-2952(89)90517-0","volume":"38","author":"T Funaki","year":"1989","unstructured":"Funaki T, Soons PA, Guengerich FP, Breimer DD (1989) In vivo oxidative cleavage of a pyridine-carboxylic acid ester metabolite of nifedipine. Biochem Pharmacol 38:4213\u20134216","journal-title":"Biochem Pharmacol"},{"key":"249_CR14","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0378-4347(93)E0449-Z","volume":"654","author":"JS Grundy","year":"1994","unstructured":"Grundy JS, Kherani R, Foster RT (1994) Sensitive high-performance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection. J Chromatogr B Biomed Appl 654:146\u2013151","journal-title":"J Chromatogr B Biomed Appl"},{"key":"249_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/bdd.2510070102","volume":"7","author":"SR Hamann","year":"1986","unstructured":"Hamann SR, Piascik MT, McAllister RG Jr (1986) Aspects of the clinical pharmacology of nifedipine, a dihydropyridine calcium-entry antagonist. Biopharm Drug Dispos 7:1\u201310","journal-title":"Biopharm Drug Dispos"},{"key":"249_CR16","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/carcin\/bgn092","volume":"29","author":"CY Han","year":"2008","unstructured":"Han CY, Cho KB, Choi HS, Han HK, Kang KW (2008) Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 29:1837\u20131844","journal-title":"Carcinogenesis"},{"key":"249_CR17","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/rcm.2881","volume":"21","author":"F He","year":"2007","unstructured":"He F, Bi HC, Xie ZY, Zuo Z, Li JK, Li X, Zhao LZ, Chen X, Huang M (2007) Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography\/mass spectrometry: application to high-throughput inhibition screening of terpenoids. Rapid Commun Mass Spectrom 21:635\u2013643","journal-title":"Rapid Commun Mass Spectrom"},{"key":"249_CR18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.2042-7158.2010.01160.x","volume":"63","author":"SP Hong","year":"2011","unstructured":"Hong SP, Yang JS, Han JY, Ha SI, Chung JW, Koh YY, Chang KS, Choi DH (2011) Effects of lovastatin on the pharmacokinetics of diltiazem and its metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin. J Pharm Pharmacol 63:129\u2013135","journal-title":"J Pharm Pharmacol"},{"key":"249_CR19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00228-005-0093-8","volume":"62","author":"LI Kajosaari","year":"2006","unstructured":"Kajosaari LI, Jaakkola T, Neuvonen PJ, Backman JT (2006) Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol 62:217\u2013223","journal-title":"Eur J Clin Pharmacol"},{"key":"249_CR20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/BF03190040","volume":"24","author":"PA Kelly","year":"1999","unstructured":"Kelly PA, Wang H, Napoli KL, Kahan BD, Strobel HW (1999) Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. Eur J Drug Metab Pharmacokinet 24:321\u2013328","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"249_CR21","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/jps.10086","volume":"91","author":"M Kuroha","year":"2002","unstructured":"Kuroha M, Kayaba H, Kishimoto S, Khalil WF, Shimoda M, Kokue E (2002) Effect of oral ketoconazole on first-pass effect of nifedipine after oral administration in dogs. J Pharm Sci 91:868\u2013873","journal-title":"J Pharm Sci"},{"key":"249_CR22","first-page":"231","volume":"15","author":"D Leveque","year":"1995","unstructured":"Leveque D, Jehl F (1995) P-glycoprotein and pharmacokinetics. Anticancer Res 15:231\u2013336","journal-title":"Anticancer Res"},{"key":"249_CR23","unstructured":"Lewis DFV (1996) Cytochrome P450. Substrate specificity and metabolism. In: Cytochromes P450. Structure, function, and mechanism. Taylor & Francis, Bristol, p 123"},{"key":"249_CR24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0031-6997(24)01402-9","volume":"51","author":"JH Lin","year":"1999","unstructured":"Lin JH, Chiba M, Baillie TA (1999) Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135\u2013158","journal-title":"Pharmacol Rev"},{"key":"249_CR25","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1248\/jhs.56.310","volume":"56","author":"A Nishimura","year":"2010","unstructured":"Nishimura A, Fujimura M, Hasengawa F, Shibata N (2010) pharmacokinetic interaction between nifedipine and Coenzyme Q10. J Health Sci 56:310\u2013320","journal-title":"J Health Sci"},{"key":"249_CR26","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/00007691-199608000-00006","volume":"18","author":"MV Relling","year":"1996","unstructured":"Relling MV (1996) Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs? Ther Drug Monit 18:350\u2013356","journal-title":"Ther Drug Monit"},{"key":"249_CR27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/03602539709037591","volume":"29","author":"S Rendic","year":"1997","unstructured":"Rendic S, Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29:413\u2013580","journal-title":"Drug Metab Rev"},{"key":"249_CR28","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1124\/dmd.31.4.439","volume":"31","author":"J Sahi","year":"2003","unstructured":"Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW (2003) Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 31:439\u2013446","journal-title":"Drug Metab Dispos"},{"key":"249_CR29","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","volume":"270","author":"T Shimada","year":"1994","unstructured":"Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414\u2013423","journal-title":"J Pharmacol Exp Ther"},{"key":"249_CR30","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2165\/00003495-198530030-00002","volume":"30","author":"EM Sorkin","year":"1985","unstructured":"Sorkin EM, Clissold SP, Brogden RN (1985) Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 30:182\u2013274","journal-title":"Drugs"},{"key":"249_CR31","first-page":"1926","volume":"48","author":"I Sugawara","year":"1988","unstructured":"Sugawara I, Kataoka I, Morishita Y, Hamada H, Tsuruo T, Itoyama S, Mori S (1988) Tissue distribution of P-glycoprotein encoded by a multidrug resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res 48:1926\u20131929","journal-title":"Cancer Res"},{"key":"249_CR32","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1073\/pnas.84.21.7735","volume":"84","author":"F Thiebaut","year":"1987","unstructured":"Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci 84:7735\u20137738","journal-title":"Proc Natl Acad Sci"},{"key":"249_CR33","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/37.2.2463300","volume":"37","author":"F Thiebaut","year":"1989","unstructured":"Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1989) Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 37:159\u2013164","journal-title":"J Histochem Cytochem"},{"key":"249_CR34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","volume":"13","author":"VJ Wacher","year":"1995","unstructured":"Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificites and tissues distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129\u2013134","journal-title":"Mol Carcinog"},{"key":"249_CR35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1177\/0091270004270642","volume":"45","author":"RL Walsky","year":"2005","unstructured":"Walsky RL, Gaman EA, Obach RS (2005) Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45:68\u201378","journal-title":"J Clin Pharmacol"},{"key":"249_CR36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1750-3841.2010.01960.x","volume":"76","author":"Y Wang","year":"2011","unstructured":"Wang Y, Zou MJ, Zhao N, Ren JG, Zhou H, Cheng G (2011) Effect of diallyl trisulfide on the pharmacokinetics of nifedipine in rats. J Food Sci 76:30\u201334","journal-title":"J Food Sci"},{"key":"249_CR37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00008571-199408000-00001","volume":"4","author":"PB Watkins","year":"1994","unstructured":"Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171\u2013184","journal-title":"Pharmacogenetics"},{"key":"249_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000328773","volume":"88","author":"SH Yang","year":"2011","unstructured":"Yang SH, Choi JS, Choi DH (2011) Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Pharmacology 88:1\u20139","journal-title":"Pharmacology"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-014-0249-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-014-0249-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-014-0249-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T17:11:45Z","timestamp":1747329105000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-014-0249-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,31]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["249"],"URL":"https:\/\/doi.org\/10.1007\/s13318-014-0249-y","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2014,12,31]]}}}